Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02750930
Recruitment Status : Terminated (The termination was result of GSK business considerations and not due to quality, safety or efficacy concerns with any albiglutide formulations or study conduct)
First Posted : April 26, 2016
Results First Posted : March 14, 2018
Last Update Posted : July 12, 2019
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
Albiglutide has been developed for the treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise, as monotherapy, or in combination with existing therapies and has been approved by the United States (US) Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other regulatory agencies. This is a 26 week, open-label, single group, multicenter, extension study to Study 200952. This extension study will provide extended safety, tolerability and immunogenicity data for the albiglutide liquid drug product. This extension study will comprise 2 study periods: treatment (26 weeks) and post-treatment follow-up (8 weeks). A maximum of 300 subjects will be eligible to take part in this extension study.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: Albiglutide Device: Auto-injector Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects With Type 2 Diabetes Mellitus
Actual Study Start Date : October 7, 2016
Actual Primary Completion Date : March 21, 2017
Actual Study Completion Date : March 21, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Albiglutide

Arm Intervention/treatment
Experimental: Albiglutide arm
Subjects will receive 50 milligrams (mg) albiglutide liquid drug product once weekly via auto-injector for 26 weeks.
Drug: Albiglutide
Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).

Device: Auto-injector
The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.




Primary Outcome Measures :
  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to Week 34 ]
    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product whether or not it is considered drug related. This would include any side effect, injury, toxicity, sensitivity reaction, abnormal or worsening of a laboratory value, concurrent illness or sudden death. Pre-existing conditions that worsen during a study will be reported as AEs. SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or extends a current hospital stay, results in an ongoing or significant incapacity or interferes substantially with normal life functions, or causes a congenital anomaly or birth defect, or is associated with liver injury or impaired liver function. Number of participants who reported any AE or SAE during this extension study or who had ongoing AE or SAE from study 200952 have been presented.

  2. Number of Participants With Physical Examination Abnormalities [ Time Frame: Up to Week 34 ]
    A full physical examination was planned to be done, at a minimum, assessment of the skin (including injection site), head, eyes, ears, nose, throat, thyroid, respiratory system cardiovascular system, abdomen (liver and spleen), lymph nodes, central nervous system and extremities was planned. The evaluation of skin (including injection site), respiratory system, cardiovascular system, abdomen (liver, spleen), and central nervous system was planned; however, it was not performed due to early termination of the study.

  3. Number of Participants With Hematology Values of Potential Clinical Importance (PCI) [ Time Frame: Up to Week 34 ]
    Blood samples were collected from the participants to evaluate the hematology paramaters. The following hematology parameters were measured: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), white blood cell (WBC) count, neutrophils, lymphocytes, monocytes, eosinophils, and basophils, at the specified timepoints (Week 0, 4, 10, 22, 26 and Week 34). Number of participants with hematology paramaters with PCI values has been reported.

  4. Number of Participants With Clinical Chemistry Parameters of PCI [ Time Frame: Up to Week 34 ]
    The following clinical chemistry parameters were measured: blood urea nitrogen (BUN), creatinine, calcium, bicarbonate, potassium, sodium, chloride, uric acid, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase, gamma glutamyl transferase (GGT), total and direct bilirubin, total protein, and albumin at the specified timepoints (Week 0, 4, 10, 22, 26 and Week 34). Number of participants with clinical chemistry paramaters with PCI values has been reported.

  5. Number of Participants With Clinically Significant Urinalysis Abnormalities by Dipstick Method [ Time Frame: Up to 26 weeks ]
    Urine samples were collected early morning from the participants at specified timepoints (Weeks 26 to 52). The following urinalysis parameters were measured: specific gravity, power of hydrogen (pH), glucose, protein, blood and ketones by dipstick; microscopic examination (if blood or protein was abnormal). Number of participants with no clinically significant abnormalities in urinalysis dipstick results were reported.

  6. Number of Participants With Pulse Rate Values of PCI [ Time Frame: Up to Week 34 ]
    The pulse rate, was measured after completion of the electrocardiogram (ECG) sampling at specified timepoints (Week 0, 4, 10, 22, 26 and Week 34). The participants were asked to be either in semi-recumbent or sitting position. During blood withdraws the vitals were performed prior to blood collection. Number of participants with pulse rate values of PCI has been reported.

  7. Number of Participants With Systolic and Diastolic Blood Pressure of PCI [ Time Frame: Up to Week 34 ]
    The systolic and diastolic blood pressure, were measured after completion of the ECG sampling at specified timepoints (Week 0, 4, 10, 22, 26 and Week 34). The participants were asked to be either in semi-recumbent or sitting position. During blood withdraws the vitals were performed prior to blood collection. Number of participants with systolic and diastolic blood pressure values of PCI has been reported.

  8. Number of Participants With Clinically Significant Findings for 12-lead ECG [ Time Frame: Up to Week 34 ]
    A single 12-lead ECG was performed at the specified timepoints (Weeks 0, 26 and 34) during the study where the participant was instructed to be in semi-recumbent position for 10 to 15 minutes before obtaining the ECG. An ECG machine that automatically calculated the heart rate and measures like the PR, QRS, QT, and corrected QT intervals. Number of participants with clinically significant findings in ECG results has been reported.

  9. Number of Participant With Positive Results of Anti-albiglutide Antibody Production Over Time [ Time Frame: Up to Week 34 ]
    Anti-albiglutide antibodies were planned to be assessed using a validated enzyme-linked immunosorbent assay, which utilized a tiered testing approach. It was to be collected at specified timepoints at Week 0, Week 4, Week 10, Week 26 and Week 34 (follow-up). Confirmed positive samples were to be titrated to obtain the titer of anti-albiglutide antibodies. The number of participants with positive results of anti-albiglutide antibody production was to be reported. However, due to early termination only limited number of key safety data was analyzed. This study 204682 was planned as an extension of the main study, 200952 and was supposed to end well after the main study. However, the 204682 extension study was terminated prior to completion of the main study 200952, which is a double-blind study. To preserve the integrity of the main study 200952, results of anti-albiglutide antibody were not completed after the termination.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who have completed the 26 week Treatment Phase of Study 200952
  • Male or female
  • Able and willing to provide informed consent.

Exclusion Criteria:

  • Subject meets one or more of the withdrawal stopping criteria at Visit 1 (Week 26)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02750930


  Hide Study Locations
Locations
Layout table for location information
United States, Arizona
GSK Investigational Site
Phoenix, Arizona, United States, 85018
United States, California
GSK Investigational Site
Fresno, California, United States, 93720
GSK Investigational Site
Lomita, California, United States, 90717
GSK Investigational Site
Sacramento, California, United States, 95831
GSK Investigational Site
Spring Valley, California, United States, 91978
GSK Investigational Site
Tustin, California, United States, 92780
GSK Investigational Site
West Hills, California, United States, 91307
United States, Colorado
GSK Investigational Site
Littleton, Colorado, United States, 80128
United States, Florida
GSK Investigational Site
Bradenton, Florida, United States, 34201
GSK Investigational Site
Clearwater, Florida, United States, 33765
GSK Investigational Site
Hallandale Beach, Florida, United States, 33009
GSK Investigational Site
Miami, Florida, United States, 33156
GSK Investigational Site
Miami, Florida, United States, 33176
GSK Investigational Site
Orlando, Florida, United States, 32825
United States, Georgia
GSK Investigational Site
Conyers, Georgia, United States, 30094
United States, Indiana
GSK Investigational Site
Evansville, Indiana, United States, 47714
United States, Michigan
GSK Investigational Site
Kalamazoo, Michigan, United States, 49009
United States, Missouri
GSK Investigational Site
Chesterfield, Missouri, United States, 63017
United States, North Carolina
GSK Investigational Site
Columbia, North Carolina, United States, 28150
United States, Ohio
GSK Investigational Site
Columbus, Ohio, United States, 43201
United States, South Carolina
GSK Investigational Site
Columbia, South Carolina, United States, 29204
United States, Texas
GSK Investigational Site
Arlington, Texas, United States, 76012
GSK Investigational Site
Dallas, Texas, United States, 75230
GSK Investigational Site
Houston, Texas, United States, 77036
GSK Investigational Site
Houston, Texas, United States, 77058
GSK Investigational Site
Schertz, Texas, United States, 782154
GSK Investigational Site
Shavano Prk, Texas, United States, 78231
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
  Study Documents (Full-Text)

Documents provided by GlaxoSmithKline:
Study Protocol  [PDF] October 28, 2015
Statistical Analysis Plan  [PDF] March 6, 2017


Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT02750930     History of Changes
Other Study ID Numbers: 204682
First Posted: April 26, 2016    Key Record Dates
Results First Posted: March 14, 2018
Last Update Posted: July 12, 2019
Last Verified: July 2019
Keywords provided by GlaxoSmithKline:
Extension
Long-term Safety
Pharmacodynamics
Albiglutide
Type 2 Diabetes Mellitus
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
rGLP-1 protein
Glucagon-Like Peptide 1
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs